MX2023004480A - Compuestos anticancerigenos selectivos para canceres er-positivos. - Google Patents
Compuestos anticancerigenos selectivos para canceres er-positivos.Info
- Publication number
- MX2023004480A MX2023004480A MX2023004480A MX2023004480A MX2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A MX 2023004480 A MX2023004480 A MX 2023004480A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- small molecule
- cancer cells
- biomodulators
- positive cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104933P | 2020-10-23 | 2020-10-23 | |
| PCT/US2021/056003 WO2022087234A1 (en) | 2020-10-23 | 2021-10-21 | Anticancer compounds selective for er-positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004480A true MX2023004480A (es) | 2023-05-04 |
Family
ID=81290080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004480A MX2023004480A (es) | 2020-10-23 | 2021-10-21 | Compuestos anticancerigenos selectivos para canceres er-positivos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12655104B2 (enExample) |
| EP (1) | EP4232038A4 (enExample) |
| JP (1) | JP2023546584A (enExample) |
| CN (1) | CN116723841A (enExample) |
| AU (2) | AU2021366688B2 (enExample) |
| CA (1) | CA3196210A1 (enExample) |
| IL (1) | IL302154A (enExample) |
| MX (1) | MX2023004480A (enExample) |
| WO (1) | WO2022087234A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120981469A (zh) * | 2023-02-23 | 2025-11-18 | 晨晖生物科技(香港)有限公司 | 含硼化合物及其治疗用途 |
| WO2026039467A1 (en) * | 2024-08-12 | 2026-02-19 | The Board Of Trustees Of The University Of Illinois | Hydroxyphenyl-indoline-2-one cancer therapeutics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2855406A (en) | 1955-05-07 | 1958-10-07 | Dann Otto | Preparation of benzopyrans and benzofurans |
| US3773759A (en) | 1972-08-21 | 1973-11-20 | Searle & Co | 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines |
| FR2810320B1 (fr) | 2000-06-19 | 2002-08-23 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| CA2684552A1 (en) * | 2007-04-24 | 2008-10-30 | Topotarget A/S | Substituted 3-(4-hydroxyphenyl)-indolin-2-one compounds |
| EA027139B1 (ru) | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| CN108440378B (zh) | 2018-03-27 | 2021-03-12 | 宁波大学 | 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法 |
| EP3817741A4 (en) * | 2018-07-03 | 2022-07-06 | The Board of Trustees of the University of Illinois | ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE |
-
2021
- 2021-10-21 WO PCT/US2021/056003 patent/WO2022087234A1/en not_active Ceased
- 2021-10-21 CA CA3196210A patent/CA3196210A1/en active Pending
- 2021-10-21 US US18/033,173 patent/US12655104B2/en active Active
- 2021-10-21 CN CN202180086814.XA patent/CN116723841A/zh active Pending
- 2021-10-21 EP EP21883881.1A patent/EP4232038A4/en active Pending
- 2021-10-21 IL IL302154A patent/IL302154A/en unknown
- 2021-10-21 MX MX2023004480A patent/MX2023004480A/es unknown
- 2021-10-21 JP JP2023524127A patent/JP2023546584A/ja active Pending
- 2021-10-21 AU AU2021366688A patent/AU2021366688B2/en active Active
-
2026
- 2026-06-02 AU AU2026204244A patent/AU2026204244A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021366688A9 (en) | 2024-06-20 |
| US12655104B2 (en) | 2026-06-16 |
| EP4232038A4 (en) | 2024-04-10 |
| IL302154A (en) | 2023-06-01 |
| AU2021366688A1 (en) | 2023-05-25 |
| JP2023546584A (ja) | 2023-11-06 |
| EP4232038A1 (en) | 2023-08-30 |
| AU2026204244A1 (en) | 2026-06-18 |
| CA3196210A1 (en) | 2022-04-28 |
| WO2022087234A1 (en) | 2022-04-28 |
| US20230391721A1 (en) | 2023-12-07 |
| CN116723841A (zh) | 2023-09-08 |
| AU2021366688B2 (en) | 2026-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| CR20210060A (es) | Activadores de la respuesta a proteínas desplegadas | |
| AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
| ZA201904652B (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2019014021A (es) | Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| SA521430960B1 (ar) | NF-κB مثبطات جزيئية صغيرة لكيناز تحفيز | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| MX2024003797A (es) | Conjugados de anticuerpos b7-h4 y farmacos para el tratamiento del cancer. | |
| PH12013502494A1 (en) | Neutralizing prolactin receptor antibody mat3 and its therapeutic use | |
| MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
| MX2024007260A (es) | Uso de terapia de combinacion para tratar el cancer. | |
| MX2022000853A (es) | Anticuerpos anti-liv1 humanizados para el tratamiento de cancer. | |
| MX2025002424A (es) | Combinacion de dcc-3116 e inhibidores de la via mapkap para su uso en el tratamiento del cancer | |
| WO2014145817A3 (en) | Novel therapeutic target for the treatment of cancers and related therapies and methods | |
| MX2019014298A (es) | Formas de dosificacion liquida para tratar el cancer. | |
| PH12021550376A1 (en) | Combination therapy | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| WO2019190927A3 (en) | Splice-switching oligonucleotides and methods of use | |
| Liu et al. | Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer | |
| WO2019006002A8 (en) | Methods of treating cancer with small molecule nf-kb inhibitors | |
| Laliscia et al. | Radiotherapy as definitive treatment of patients with primary vulvar carcinoma unfit for surgery and with recurrent vulvar carcinoma after primary radical surgery: results of a retrospective single-center study | |
| Ritter | Commentary on “Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911).” Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France.: Lancet 2012; 380 (9858): 2018–27 |